Roche

Business briefs: Layoffs at Roche and Merck, plus pipeline news

Merck and Roche Diagnostics announce job cuts; Novartis abandons an Afinitor study; an FDA advisory committee gives Bayer's lung drug the nod; Vivus still has no plans for Qsymia DTC; and Isis drops development of a mid-stage RA drug

Roche's Rituxan successor receives high marks

By

Genentech's blockbuster follow-up shows promise in preliminary Phase III data

Tarceva diagnostic brings new indication

Tarceva diagnostic brings new indication

By

Tarceva picks up a first-line indication and a companion diagnostic

Email Newsletters